Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice. - Rinotas V; Ntouskou ED; Dragolia M; Ntafis V; Yavropoulou MP; Anastasilakis AD; Makras P; Douni E (Frontiers in endocrinology, 2026)